MetaCap

Denali Therapeutics (DNLI) vs Tarsus Pharmaceuticals (TARS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Denali Therapeutics (DNLI) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 2.5% versus a loss of 8.3%. Over five years, TARS leads with a +192.0% price change compared with -59.0% for DNLI. Tarsus Pharmaceuticals is the larger company by market cap ($3.60 billion vs $2.96 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DNLI+2.50%TARS-8.35%
+55%+11%-34%
Nov 21, 20251 yearNov 20, 2026
DNLI-60.84%TARS+191.22%
+279%+94%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DNLI versus TARS key metrics
MetricDNLITARS
Share price$18.45$73.01
Market cap$2.96B$3.60B
1-day change+1.37%-6.00%
YTD return+11.75%-10.83%
1-year return+2.50%-8.35%
5-year return-59.02%+192.04%
Forward P/E—339.58
EPS (TTM)$-1.72$-15.86
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$451.36M
Revenue growth (YoY)—+146.71%
Net income (latest FY)$-512.54M$-66.42M
Operating margin—-15.72%
Net margin—-14.72%
52-week high$27.30$91.53
52-week low$15.34$53.89
Distance from 52-week high-32.42%-20.23%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+94.15%+41.68%
Average volume1.68M871.07K
Shares outstanding160.29M49.31M
Employees503370
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DNLI has outperformed TARS by 10.8 percentage points over the past year.

About Denali Therapeutics

DNLI stock →

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees

About Tarsus Pharmaceuticals

TARS stock →

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees

DNLI vs TARS FAQ

Which is bigger, Denali Therapeutics or Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.60B compared with $2.96B for Denali Therapeutics (DNLI).

Which stock has performed better over the past year, DNLI or TARS?

DNLI returned +2.50% over the past 12 months, compared with -8.35% for TARS (price return, excluding dividends). Past performance does not predict future results.

Are Denali Therapeutics and Tarsus Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons